Most Recent
Following the failure of two class actions to prove market-based loss from the Commonwealth Bank’s disclosure breaches, the bank is fighting the class actions' bid to pursue individual ‘no transaction’ cases, saying they were “trying to keep something alive that is truly dead”.
Two class actions against Commonwealth Bank have partially succeeded on appeal, with a finding that the bank breached its continuous disclosure obligations, but damages still elude shareholders.
Pharmacor will be allowed to sell a generic version of heart drug Entresto after the Full Court rejected Swiss drug giant Novartis' appeal of a ruling that found an extension of the term of its patent for the drug was invalidly granted.
Vittoria Cantarella has taken the fight to revive its ‘Oro’ trade marks to the High Court, arguing the Full Court should have found it was an honest concurrent user of the marks, which were first used by another coffee maker.
The High Court won't hear Bayer's appeal of an invalidity finding over patents for blood thinner Xarelto, despite the company's claim the decision has "profound" consequences for drug R&D.
The Full Court has poured cold water on Vittoria Cantarella's hopes of reviving its ‘Oro’ trade marks, finding a judge did not err in concluding the marks were already used by another coffee maker.
Pharmaceutical giant Novartis is challenging the loss of its case against Sydney-based generics company Pharmacor over a patent for heart medication Entresto.
A judge has deferred the question of what penalties Harvey Norman and Latitude Finance should face in a case by ASIC until their appeals are heard, noting the “regrettable” fragmentation of the case.
The Full Court has overturned a finding that singer Katy Perry infringed an Australian fashion designer's 'Katie Perry' mark, finding the designer knew of the pop star when she registered the mark.